Mark Strobeck Ph.d.

Biography

Dr. Mark Strobeck, PhD., has been the Chief Operating Officer and Executive Vice President at Egalet Corporation since September 2015. Dr. Strobeck served as the Chief Business Officer of Egalet Corporation since January 2014 until September 2015 and serves as its Head of Strategic Planning until October 5, 2015. Previously, he served as an Adviser to Egalet from June 2012 to December 2013. He served as the Chief Executive Officer and President of Corridor Pharmaceuticals, Inc. from January 2012 to December 2013. He served as the Chief Business Officer and Vice President of Topaz Pharmaceuticals Inc. from December 2010 to October 2011 and was responsible for managing business development, corporate strategy and financings. From June 2010 to November 2010 and October 2011 to January 2012, he worked as a Consultant. Dr. Strobeck has decades of experience in the pharmaceutical and financial industry. He served as an Associate at EuclidSR Partners, L.P. He served as Chief Business Officer at Trevena, Inc. from January 2008 to May 2010. Prior to Trevena, he served as Vice President of business development at GlaxoSmithKline plc (GSK) where he led the business development efforts for GSK's clinical and preclinical stage assets. He also served as Vice President of Business Development at the center of excellence for external drug discovery, a research and development division within GSK. Prior to this, he served as Principal and Senior Associate of SR One Limited. He served as Vice President of Business Development for Drug Discovery at GlaxoSmithKline. Previously, Dr. Strobeck was Vice President at the Center of Excellence for External Drug Discovery (CEEDD), an innovative organization responsible for building an external drug discovery portfolio via a network of business development relationships. He served in the Division of Cardiovascular Medicine of the University of Pennsylvania. He spent eight years in cardiovascular and Neuro-pharmacology research, participating in collaborations with many pharmaceutical companies including sponsored research with Tanabe Seiyaku Co. He also serves as a Board Observer of Scion Pharmaceuticals Inc. He serves as a Member of the Scientific Advisory Board at IndiPharm, Inc.

Research Interest

He served as a Director of Corridor Pharmaceuticals, Inc. from January 2012 to December 2013. He served as a Board Observer of AlgoRx Pharmaceuticals, Inc., Conforma Therapeutics, Inc., Rib-X Pharmaceuticals and Santarus, Inc. Dr. Strobeck served as a Director of Protein Forest, Inc. He served as a Director of Novalar Pharmaceuticals, Inc. He served as a Board Observer to Fluidigm Corp. and KuDOS Pharmaceuticals. He has been on the board of directors of Horse Power For Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer since 2012. He holds a Ph.D. in Pharmacology and cell Biophysics from the University of Cincinnati and a B.Sc. in biology from St. Lawrence University. Dr. Strobeck completed a post-doctoral fellowship in cardiovascular medicine at the University of Pennsylvania.